Evident Vascular is a technology company.
Evident Vascular has raised $35.0M across 1 funding round.
Evident Vascular has raised $35.0M in total across 1 funding round.
Evident Vascular is a medtech startup developing an AI-powered intravascular ultrasound (IVUS) platform optimized for peripheral vascular interventions, with plans to expand to coronary procedures.[1][2][4] The Evident Vascular Guidance System serves interventional cardiologists and vascular specialists treating peripheral arterial and venous diseases, solving key limitations in current IVUS tools—such as suboptimal image quality, complex workflows, and poor navigation in peripheral vasculature—by delivering superior imaging, AI-driven interpretation, and streamlined clinical decision-making for better patient outcomes.[1][3][4] Launched in 2023 with $35M in Series A funding led by Vensana Capital, the company raised additional Series B financing in March 2025 from Shangbay Capital and strategics, fueling FDA 510(k) clearance and U.S. market launch amid rising peripheral vascular disease prevalence.[2][4][5]
Evident Vascular emerged from Vensana Capital's incubation in 2023, exiting stealth on October 17 with a $35M Series A round led by the firm.[4][8] Co-founders Howard Rosen (CEO), Patrick Phillips, Ph.D. (CTO), and Danielo Piazza (CPO) bring deep expertise in vascular medical devices, catheter-based ultrasound, diagnostic imaging, and image-guided therapy.[4] The idea stemmed from a recognized gap: while treatments for peripheral vascular disease (PVD) have advanced, diagnostic IVUS tools lag, forcing trade-offs in image quality and workflow fit, as noted by clinicians.[3][4][7] Early traction included Vensana's backing, highlighting the team's potential to pioneer next-gen IVUS, with Series B in 2025 accelerating development toward commercialization.[2][5]
Evident Vascular rides the surge in peripheral vascular disease driven by aging populations and rising arterial/venous conditions, where IVUS is becoming the standard of care but remains underutilized due to outdated tech.[2][5][7] Timing aligns with AI's maturation in medtech for imaging analysis, enabling precise diagnostics amid expanding PVD therapies—market forces like clinical guidelines favoring IVUS and investor confidence (e.g., Series B from strategics) amplify this.[2][3][5] It influences the ecosystem by disrupting a stagnant IVUS market, potentially increasing adoption, improving procedural success, and setting benchmarks for AI in vascular care, with expansion to coronary applications broadening impact.[1][4]
Evident Vascular is primed for U.S. launch post-FDA clearance, leveraging Series B momentum to deploy its platform and capture share in a ripe IVUS market.[5][6] Trends like AI integration in diagnostics and PVD prevalence will propel growth, with coronary expansion unlocking larger opportunities. Its influence may evolve from innovator to category leader, empowering clinicians with tools that redefine vascular interventions—transforming patient care as IVUS disruption takes hold, much like its founding vision promised.[1][4]
Evident Vascular has raised $35.0M in total across 1 funding round.
Evident Vascular's investors include HighlandX, Vensana Capital, Bradley Horowitz.
Evident Vascular has raised $35.0M across 1 funding round. Most recently, it raised $35.0M Series A in October 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2023 | $35.0M Series A | HighlandX, Vensana Capital, Bradley Horowitz |